|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALG1L |
Gene summary for ALG1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALG1L | Gene ID | 200810 |
| Gene name | ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase like | |
| Gene Alias | ALG1L1 | |
| Cytomap | 3q21.2 | |
| Gene Type | pseudo | GO ID | GO:0006464 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 200810 | ALG1L | LZE2T | Human | Esophagus | ESCC | 2.18e-04 | 4.66e-01 | 0.082 |
| 200810 | ALG1L | LZE4T | Human | Esophagus | ESCC | 1.25e-18 | 4.98e-01 | 0.0811 |
| 200810 | ALG1L | LZE7T | Human | Esophagus | ESCC | 8.50e-13 | 5.35e-01 | 0.0667 |
| 200810 | ALG1L | LZE8T | Human | Esophagus | ESCC | 4.82e-12 | 4.06e-01 | 0.067 |
| 200810 | ALG1L | LZE20T | Human | Esophagus | ESCC | 4.18e-08 | 2.82e-01 | 0.0662 |
| 200810 | ALG1L | LZE22D1 | Human | Esophagus | HGIN | 1.90e-05 | 2.38e-01 | 0.0595 |
| 200810 | ALG1L | LZE22T | Human | Esophagus | ESCC | 1.57e-02 | 2.80e-01 | 0.068 |
| 200810 | ALG1L | LZE24T | Human | Esophagus | ESCC | 7.36e-33 | 6.94e-01 | 0.0596 |
| 200810 | ALG1L | LZE21T | Human | Esophagus | ESCC | 1.97e-09 | 5.47e-01 | 0.0655 |
| 200810 | ALG1L | LZE6T | Human | Esophagus | ESCC | 4.35e-10 | 4.51e-01 | 0.0845 |
| 200810 | ALG1L | P1T-E | Human | Esophagus | ESCC | 1.42e-19 | 8.74e-01 | 0.0875 |
| 200810 | ALG1L | P2T-E | Human | Esophagus | ESCC | 3.75e-03 | 8.08e-02 | 0.1177 |
| 200810 | ALG1L | P4T-E | Human | Esophagus | ESCC | 1.01e-26 | 5.90e-01 | 0.1323 |
| 200810 | ALG1L | P5T-E | Human | Esophagus | ESCC | 2.93e-15 | 3.00e-01 | 0.1327 |
| 200810 | ALG1L | P8T-E | Human | Esophagus | ESCC | 2.49e-44 | 8.37e-01 | 0.0889 |
| 200810 | ALG1L | P9T-E | Human | Esophagus | ESCC | 5.60e-20 | 4.46e-01 | 0.1131 |
| 200810 | ALG1L | P11T-E | Human | Esophagus | ESCC | 2.88e-23 | 9.21e-01 | 0.1426 |
| 200810 | ALG1L | P12T-E | Human | Esophagus | ESCC | 1.23e-20 | 4.29e-01 | 0.1122 |
| 200810 | ALG1L | P15T-E | Human | Esophagus | ESCC | 2.05e-65 | 1.17e+00 | 0.1149 |
| 200810 | ALG1L | P20T-E | Human | Esophagus | ESCC | 1.25e-36 | 7.81e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
| GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
| GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALG1L | SNV | Missense_Mutation | novel | c.363A>T | p.Glu121Asp | p.E121D | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| ALG1L | SNV | Missense_Mutation | rs371544045 | c.149N>T | p.Thr50Met | p.T50M | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ALG1L | SNV | Missense_Mutation | novel | c.609G>T | p.Gln203His | p.Q203H | protein_coding | deleterious_low_confidence(0.01) | benign(0.102) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALG1L | SNV | Missense_Mutation | rs139400046 | c.571N>A | p.Pro191Thr | p.P191T | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
| ALG1L | SNV | Missense_Mutation | novel | c.73G>A | p.Ala25Thr | p.A25T | protein_coding | tolerated(0.1) | possibly_damaging(0.584) | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ALG1L | SNV | Missense_Mutation | novel | c.253T>C | p.Ser85Pro | p.S85P | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALG1L | SNV | Missense_Mutation | novel | c.445N>G | p.Leu149Val | p.L149V | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-DD-AAVR-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ALG1L | SNV | Missense_Mutation | rs373951263 | c.121N>A | p.Glu41Lys | p.E41K | protein_coding | tolerated(0.61) | benign(0.22) | TCGA-55-7911-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ALG1L | SNV | Missense_Mutation | rs770698301 | c.587N>A | p.Arg196His | p.R196H | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-MF-A522-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD | |
| ALG1L | SNV | Missense_Mutation | rs368430945 | c.119N>A | p.Arg40His | p.R40H | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-CQ-A4C9-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |